PhotoBarr

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

porfimer sodium

Disponible depuis:

Pinnacle Biologics B.V. 

Code ATC:

L01XD01

DCI (Dénomination commune internationale):

porfimer sodium

Groupe thérapeutique:

Antineoplastic agents

Domaine thérapeutique:

Barrett Esophagus

indications thérapeutiques:

Photodynamic therapy (PDT) with PhotoBarr is indicated for: Ablation of high-grade dysplasia (HGD) in patients with Barrett's Oesophagus (BO)

Descriptif du produit:

Revision: 9

Statut de autorisation:

Withdrawn

Date de l'autorisation:

2004-03-25

Notice patient

                                Medicinal product no longer authorised
42
B. PACKAGE LEAFLET
Medicinal product no longer authorised
43
PACKAGE LEAFLET: INFORMATION FOR THE USER
PHOTOBARR 15 MG POWDER FOR SOLUTION FOR INJECTION
Porfimer sodium
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE.
-
Keep this leaflet. You may need to read it again
-
If you have any further questions, please ask your doctor or
pharmacist.
-
If any of the side effects gets serious, or if you notice any side
effects not listed in this leaflet,
please tell your doctor or pharmacist.
IN THIS LEAFLET
:
1.
What PhotoBarr is and what it is used for
2.
Before you use PhotoBarr
3.
How to use PhotoBarr
4.
Possible side effects
5
How to store PhotoBarr
6.
Further information
1.
WHAT PHOTOBARR IS AND WHAT IT IS USED FOR
PhotoBarr
is a light-activated medicine used in photodynamic therapy (PDT) in
combination with a
non-burning red laser light. PDT specifically targets and destroys
abnormal cells.
PhotoBarr is used to remove high-grade dysplasia (cells with atypical
changes that increase the risk of
developing cancer) in patients with Barrett's oesophagus (gullet).
2.
BEFORE YOU USE PHOTOBARR
DO NOT USE PHOTOBARR
-
if you are allergic (hypersensitive) to porfimer sodium, other
porphyrins or any of the other
ingredients of PhotoBarr (listed in section 6, ‘
_What PhotoBarr contains’_
)
-
if you have porphyria
-
if you have an opening (fistula) between the oesophagus and the
airways
-
if you suffer from varices of your oesophageal veins or erosion of
other major blood vessels
-
if you have ulcers in your oesophagus
-
if you have severe liver or kidney problems
TAKE SPECIAL CARE WITH PHOTOBARR
Tell your doctor if any of the following applies to you:
-
you are taking any other medicines (see below),
-
you have a liver or kidney problems
-
you have a family history of cataracts
-
you are 75 years or older,
-
you have or have had heart or lung disease
PhotoBarr should not be used in children and adolescents below 18
years of age, due to lack of
experience.
Medi
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
PhotoBarr 15 mg powder for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each vial contains 15 mg porfimer sodium. After reconstitution, each
ml solution contains 2.5 mg
porfimer sodium.
For a full list of excipients, see 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for injection.
A dark red to reddish brown lyophilised powder or cake.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Photodynamic therapy (PDT) with PhotoBarr is indicated for ablation of
high-grade dysplasia (HGD)
in patients with Barrett's Oesophagus (BO).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Photodynamic therapy with PhotoBarr should be performed only by, or
under the supervision of, a
physician with experience in endoscopic laser procedures. The
medicinal product should only be
administered when material and personnel experienced in evaluating and
treating anaphylaxis are
immediately available.
Posology
The recommended dose of PhotoBarr is 2 mg/kg body weight.
Reconstituted PhotoBarr solution (ml) = Patient's weight (kg) x 2
mg/kg
= 0.8 x patient's weight
2.5 mg/ml
After reconstitution, PhotoBarr is a dark red to reddish brown, opaque
solution.
Only a solution without particles should be used and without visible
signs of deterioration.
Photodynamic therapy with PhotoBarr is a two-stage process requiring
administration of both
medicinal product and light. One course of PDT consists of one
injection plus one or two light
applications.
In case of persistence of HGD, further treatment courses (up to a
maximum of three courses) may be
given (separated by a minimum of 90 days) to increase the response
rate. This has to be balanced
against the increased rate of stricture formation (see section 4.8 and
section 5.1).
Progression to cancer was related to the number of PDT courses
administered. Patients who received
one course of PDT had a greater risk of progressi
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation bulgare 07-05-2012
Notice patient Notice patient espagnol 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation espagnol 07-05-2012
Notice patient Notice patient tchèque 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation tchèque 07-05-2012
Notice patient Notice patient danois 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation danois 07-05-2012
Notice patient Notice patient allemand 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation allemand 07-05-2012
Notice patient Notice patient estonien 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation estonien 07-05-2012
Notice patient Notice patient grec 07-05-2012
Notice patient Notice patient français 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation français 07-05-2012
Notice patient Notice patient italien 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation italien 07-05-2012
Notice patient Notice patient letton 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation letton 07-05-2012
Notice patient Notice patient lituanien 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation lituanien 07-05-2012
Notice patient Notice patient hongrois 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation hongrois 07-05-2012
Notice patient Notice patient maltais 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation maltais 07-05-2012
Notice patient Notice patient néerlandais 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation néerlandais 07-05-2012
Notice patient Notice patient polonais 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation polonais 07-05-2012
Notice patient Notice patient portugais 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation portugais 07-05-2012
Notice patient Notice patient roumain 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation roumain 07-05-2012
Notice patient Notice patient slovaque 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation slovaque 07-05-2012
Notice patient Notice patient slovène 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation slovène 07-05-2012
Notice patient Notice patient finnois 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation finnois 07-05-2012
Notice patient Notice patient suédois 07-05-2012
Rapport public d'évaluation Rapport public d'évaluation suédois 07-05-2012
Notice patient Notice patient norvégien 07-05-2012
Notice patient Notice patient islandais 07-05-2012

Rechercher des alertes liées à ce produit

Afficher l'historique des documents